Skip to main content
Premium Trial:

Request an Annual Quote

Analysis Suggests Decreased Effectiveness

The SARS-CoV-2 vaccine from Johnson & Johnson may be less effective against the Delta and Lambda viral variants, the New York Times reports.

In a preprint posted to BioRxiv, a team of New York University researchers compared the neutralizing antibody titers elicited by the J&J, Pfizer-BioNTech, and Moderna vaccines by viral variants. They found that while the Pfizer-BioNTech and Moderna vaccines exhibited modest neutralization against the viral variants tested, the J&J vaccine showed decreased neutralization against Delta and Lambda.

"The message that we wanted to give was not that people shouldn't get the J&J vaccine, but we hope that in the future, it will be boosted with either another dose of J&J or a boost with Pfizer or Moderna," study author Nathaniel Landau from NYU tells the Times.

The Times notes that this analysis, which has yet to undergo peer review, contrasts with analyses from J&J that indicate that the vaccine is effective against the Delta variant. A J&J spokesperson adds there that the data "do not speak to the full nature of immune protection" and that their own studies showed the vaccine "generated strong, persistent activity against the rapidly spreading Delta variant."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.